RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells
RhoGDI2 confers resistance to 5-fluorouracil in human gastric cancer cells
复制标题
RhoGDI2 赋予人胃癌细胞对 5-氟尿嘧啶的耐药性
DOI：
10.3892/ol.2012.949
复制
发表时间：
2013-01-01
期刊：
影响因子：
2.9
通讯作者：
Liu, Bing-Ya
中科院分区：
文献类型：
--
作者：
Zheng, Zhong;He, Xiang-Yi;Liu, Bing-Ya
胃癌患者对5-氟尿嘧啶（5-FU）的耐药是一个严重的治疗问题，目前正在努力了解其潜在机制。我们以前已经确定RhoGD 12作为一个贡献者5-FU耐药的结肠癌细胞使用2D电泳和质谱，目前的研究旨在进一步研究这一作用。RhoGD 12在7株胃癌细胞系中的表达与5-FU耐药呈正相关。从胃癌患者分离的肿瘤细胞的5-FU敏感性较低也与RhoGD 12表达较高相关。RhoGD 12在胃癌细胞中的异位表达增加了对5-FU的耐药性，并逆转了低剂量5-FU诱导的G2/M期阻滞，而不影响sub-G1细胞的群体。总体而言，这些发现表明RhoGD 12与5-FU耐药相关，是增强胃癌化疗疗效的潜在治疗靶点。
Resistance to 5-fluorouracil (5-FU) in patients with gastric cancer is a serious therapeutic problem and major efforts are underway to understand the underlying mechanisms. We have previously identified RhoGD12 as a contributor to 5-FU resistance in colon cancer cells using 2D electrophoresis and mass spectrometry and the current study aimed to further investigate this role. The expression of RhoGD12 in seven gastric cancer cell lines was positively correlated with resistance to 5-FU. Lower 5-FU sensitivity of isolated tumor cells from patients with gastric cancer was also associated with higher RhoGD12 expression. Ectopic expression of RhoGD12 in gastric cancer cells increased the resistance to 5-FU and reverted low dose 5-FU-induced G2/M phase arrest without affecting the population of sub-G1 cells. Overall, these findings suggest that RhoGD12 is associated with 5-FU resistance and is a potential therapeutic target for enhancing chemotherapy efficacy in gastric cancer.